TSL.L Regulatory News (TSL)

16 Nov 2006 08:37

Tissue Science Laboratories PLC16 November 2006 For immediate release 16 November 2006 Tissue Science Laboratories plc ("TSL" or the "Company") Directors' Dealings Tissue Science Laboratories plc announces the subscription for New OrdinaryShares by five of its directors, Patrick Paul, David Jennings, David Lindop,Andrew Sealey and Martin Hunt, the intention of which was announced on 23October 2006 as part of the Placing announced by the Company on 23 October 2006(the "Placing"). The subscriptions by the five directors are on the same termsas the other investors in the Placing at the price of 55 pence per New OrdinaryShare, following approval of shareholders at the EGM which took place on 15November 2006. The New Ordinary Shares were admitted to trading on AIM today. Patrick Paul, Non-Executive Chairman of the Company, subscribed for 1,014,618New Ordinary Shares pursuant to the Placing. Prior to the Placing, Mr. Paul wasinterested in 5,882,440 Ordinary Shares (representing 19.93 per cent of theCompany's issued share capital). Following completion of the Placing, Mr. Paulis interested in 6,897,058 Ordinary Shares (representing 19.93 per cent of theCompany's issued share capital, as enlarged by the Placing). Martin Hunt, Chief Executive Officer of the Company, subscribed for 18,181 NewOrdinary Shares in TSL, representing 0.05 per cent of the issued share capitalof the Company following completion of the Placing (the "Enlarged Issued ShareCapital"). Following the Placing, Mr. Hunt has a total holding of 33,587Ordinary Shares, representing 0.10 per cent of the Enlarged Issued Share Capitalof the Company. David Jennings, Finance Director of the Company, subscribed for 13,636 NewOrdinary Shares in TSL, representing 0.04 per cent of the Enlarged Issued ShareCapital of the Company. Following the Placing, Mr. Jennings holds a total of23,193 Ordinary Shares, representing 0.07 per cent of the Enlarged Issued ShareCapital of the Company. David Lindop, Non-executive Director of the Company, subscribed for 18,181 NewOrdinary Shares in TSL, representing 0.05 per cent of the Enlarged Issued ShareCapital of the Company. Following the Placing, Mr. Lindop holds a total of18,181 Ordinary Shares, representing 0.05 per cent of the Enlarged Issued ShareCapital of the Company. Andrew Sealey, Non-executive Director of the Company, subscribed for 33,979 NewOrdinary Shares in TSL, representing 0.10 per cent of the Enlarged Issued ShareCapital of the Company. Following the Placing, Mr. Sealey holds a total of230,947 Ordinary Shares, representing 0.67 per cent of the Enlarged Issued ShareCapital of the Company. Enquiries: Tissue Science Laboratories Plc 01252 369603Martin Hunt, Chief ExecutiveDavid Jennings, Finance Director Nomura Code Securities LimitedJuliet Thompson 0207 7761204Clare Terlouw 0207 7761205 Hogarth Partnership Limited 0207 357 9477James LongfieldSarah Richardson This information is provided by RNS The company news service from the London Stock Exchange